Immune cell therapy takes on tough endometrial cancer
NCT ID NCT06481592
First seen Nov 01, 2025 · Last updated Jun 21, 2026 · Updated 29 times
Summary
This phase 2 trial tests a personalized cell therapy called lifileucel (TIL) in 60 people with advanced endometrial cancer that has been treated before. Doctors take a sample of the patient's tumor, grow immune cells from it in a lab, and then infuse them back after a short course of chemotherapy. The goal is to see if this approach can shrink tumors or stop them from growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Allegheny Health
RECRUITINGPittsburgh, Pennsylvania, 15524, United States
-
Augusta University
RECRUITINGAugusta, Georgia, 30912, United States
-
Avera Medical Group Oncology
RECRUITINGSioux Falls, South Dakota, 57105, United States
-
Barbara Ann Karmanos Cancer Hospital
RECRUITINGDetroit, Michigan, 48201, United States
-
H. Lee Moffitt Cancer Center and Research Institute, Inc.
RECRUITINGTampa, Florida, 33612, United States
-
Honor Health
RECRUITINGPhoenix, Arizona, 85016, United States
-
MD Anderson Cancer Center - U of Texas
RECRUITINGHouston, Texas, 77030, United States
-
Orlando Health
RECRUITINGOrlando, Florida, 32806, United States
-
Roswell Park Cancer Institute
RECRUITINGBuffalo, New York, 14203, United States
-
University of Oklahoma
RECRUITINGOklahoma City, Oklahoma, 73117, United States
-
University of Southern California
RECRUITINGLos Angeles, California, 90007, United States
-
UofL Health - Brown Cancer Center
RECRUITINGLouisville, Kentucky, 40202, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lifileucel (tumor-infiltrating lymphocytes, TIL)
What this could lead to
If it works, this could offer a new treatment option for advanced endometrial cancer that has not responded to prior therapies.
What could go wrong
This is an early-phase trial with only 60 participants, so results may not apply to everyone. The treatment involves strong chemotherapy and IL-2, which can cause serious side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.